Can you please start by providing a brief overview of CELLforCURE’s history and how the company has
developed since being founded?

Founded in 2010 by LFB, a French government-owned pharmaceutical company, CELLforCURE was created to pioneer manufacturing in the emerging field of cell & gene therapy. Designed as one of the first specialised CDMOs in Europe, CELLforCURE built a GMP facility tailored to ATMP (Advanced Therapy Medicinal Products) production.

In 2015, CELLforCURE reached a major milestone when it received GMP authorisation from the ANSM, allowing it to manufacture ATMPs for both clinical and commercial use in Europe. This recognition positioned CELLforCURE as a trusted manufacturing partner in the growing cell therapy ecosystem. In 2016, CELLforCURE manufactured clinical vials of an allogeneic CAR-T cell therapy, marking one of the first GMP
productions of its kind in Europe.

In 2019, Novartis acquired CELLforCURE and, from 2020 to 2023, CELLforCURE produced the first approved autologous CAR-T therapy. In 2023, following a strategic decision made by Novatis, SEQENS acquired CELLforCURE, marking a new chapter. Now under SEQENS, CELLforCURE continues to deliver end-to-end
CDMO services in ATMP manufacturing from early clinical phases to commercial supply, leveraging more than a decade of operational and regulatory expertise.

Today, CELLforCURE by SEQENS remains one of the key CDMOs in Europe dedicated to the manufacturing of innovative cell and gene therapies.